Pin26 Economic Evaluation of Sunitinibvs. Interferon-Alfa (Ifn-Alfa) in First-Line Treatment of Metastatic Renal Cell Carcinoma (Mrcc) in Colombia

Godoy, JI; Cardona, AF; Alvis, Nelson; Arango, CH; Romero, Míriam; Spath, A; Ramírez, Porfirio Hernández; Caceres, HA; Quijano, MF

doi:10.1016/s1098-3015(10)70324-7

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The principal findings in the US clinical scenario were: sunitinib was associated with a gain in LYG of 0.41 and 0.35 over IFN and IL-2, respectively. Similarly, the gain estimated with sunitinib over that of IFN was 0.11 LYG and 0.14 QALY, results concordant with the data described in Colombia 26 . In our country, sunitinib was more effective and less costly in a temporal horizon of 1 year.…”

Section: Discussionsupporting

confidence: 89%

“…Recently, Remak et al presented the final results of the complete economic analysis of 3 interventions (IFN, IL-2 and sunitinib) used most frequently in the treatment of mRCC in the USA 24 , The study included variables similar to those described in the evaluation of sunitinib vs. IFN as first-line treatment of mRCC initially developed by our group for Colombia 26 . The principal findings in the US clinical scenario were: sunitinib was associated with a gain in LYG of 0.41 and 0.35 over IFN and IL-2, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis.

Cardona¹,

Godoy²,

Cáceres³

et al. 2012

Rev.Col.Hematol.Oncol

View full text Add to dashboard Cite

Objective: To perform a local study based on an economic evaluation of first-line treatment of metastatic renal cell carcinoma in Colombia, since 2006-2007. Methods: We developed a Markov model using 6-week cycles to evaluate the cost-effectiveness of 4 interventions (IFN, sunitinib, bevacizumab + IFN, sorafenib) used as standard first-line treatment for mRCC in Colombia. The model used the thirdparty payer perspective and a 10-year time-line with all patients continuing with active treatment until progression, when it became acceptable to proceed to a second-line treatment or best supportive care (BSC). Results: Incremental analysis indicated a difference of US$21.796 in the average total cost of treatment when sunitinib was compared to IFN. Opposite, comparing sorafenib and bevacizumab + IFN to sunitinib demonstrated that the average total cost was less for sunitinib by US$25.857 and US$110.947 respectively. The ratios of incremental cost-effectiveness by life years gained (LYG) demonstrated sunitinib’s cost saving compared to sorafenib and the combination of bevacizumab + IFN, and an average by LYG of US$50.564,25 compared to IFN. Uncertainy is principally about sample size analized for Colombian population data. Conclusions: Sunitinib was the most cost-effective option as first-line treatment for mRCC patients in Colombia (2006- 2007), compared with the other available options. Current pharmacoeconomic data is important to improve knowledge and define the best sequence model to treat this disease in our country.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%